Overview
John Huang of MWE China Law Offices noted that “more and more” multinational pharmaceutical firms doing business in China “have been visited by the SAIC [State Administration for Industry and Commerce] in the wake of the GSK case,” in which that agency played a lead role in bringing corruption charges against executives of Glaxosmithkline. Read the full article